Document Type

Original Article



Coronavirus disease 2019 (COVID-19) pandemic is one of the deadliest pandemics of our time. Vaccines are our best hope to put an end to this pandemic. An emergency use authorization (EUA) has been given to seven vaccines and more than 4 billion doses have been globally administered. Because of EUA, the large-scale safety trials were not conducted before their use and adverse effects were one of the chief concerns resulting in vaccine hesitancy.

METHODS: This is a retrospective observational study. All the inpatients admitted to the Department of Neurology, Aga Khan University during the period from 1st April 2021 to 31st July 2021 with a recent history of COVID-19 vaccination within previous 8 weeks were included in this study. Patients with the pre-existing neurological condition were excluded.

RESULTS: Eleven patients were included in the study. Most of our patients were male (82%; n=9) with a median age of 53 14.6 years. 6 of these patients received the Sinopharm vaccine and 2 received AstraZeneca. Six patients had stroke, two had cerebral venous thrombosis, and onepatient each had autonomic neuropathy, transverse myelitis, and seizures. The majority of the patients presented within 4 weeks post-vaccination. No mortality was noted. The mean discharge mRS was 1.1. Only one patient had a history of previous COVID-19 infection.


Almost three-quarters (73%) of inpatients with a recent COVID-19 vaccination had a cerebrovascular disease. This may be a coincidental finding or may indicate a probable association. Our patients also had multiple risk factors in addition to a recent history of COVID-19 vaccination. The potential neurological sequelae of the COVID-19 vaccine will be unraveled as the vaccinated population increases

Included in

Neurology Commons